Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.

Abstract

GW501516 increased the hepatic removal of VLDL particles, which might have resulted from decreased apoC-III concentration. GW501516 increased apoA-II production, resulting in an increased concentration of LpA-I:A-II particles.

This study elucidates the mechanism of action of this PPAR-δ agonist on lipoprotein metabolism and supports its potential use in treating dyslipidemia in obesity.

Full Text

• DOI - (DOI)
• Ovid Technologies, Inc. - full-text online
• HighWire Press - full-text online
• EBSCO - full-text online

Subjects

• Adult
• Apolipoprotein A-I
• Apolipoprotein A-II
• Apolipoproteins B
• Apolipoproteins C
• Cholesterol
• Cross-Over Studies
• Double-Blind Method
• Dyslipidemias
• Humans
• Kinetics
• Lipids
• Lipoproteins
• Lipoproteins, HDL
• Lipoproteins, LDL
• Lipoproteins, VLDL
• Male
• Middle Aged
• Obesity, Abdominal
• PPAR delta
• Thiazoles
• Triglycerides

Similar articles

• Angiopoietin-like 4 mediates PPAR delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes. (2012-10-04)
• Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. (2012-07-19)
• The peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 prevents TNF-α-induced NF-κB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1. (2011-01-17)
• Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. (2006-10-26)
• PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells. (2008-05-28)
• Activation of peroxisome proliferator-activated receptor beta/delta induces lung cancer growth via peroxisome proliferator-activated receptor coactivator gamma-1alpha. (2009-02-10)
• Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. (2008-01-29)
• Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. (2007-01-18)
• Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. (2006-04-17)

Authors

• Esther M M Ooi
• Gerald F Watts
• Dennis L Sprecher
• Dick C Chan
• P Hugh R Barrett

Publication date

2011-10-06

Journal

Journal topics

• Endocrinology
• Metabolism

Language

Eng.

Copyright

Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, GPO Box X2213, Perth, Western Australia 6847, Australia.

Release reference

J Clin Endocrinol Metab. 2011 Oct;96(10):E1568-76

Related books

• Books of Apolipoprotein A-I
• Books of Apolipoprotein A-II
• Books of Apolipoproteins B
• Books of Apolipoproteins C
• Books of Cholesterol
• Books of Cross-Over Studies
• Books of Double-Blind Method
• Books of Dyslipidemias
• Books of Endocrinology
• Books of Kinetics
• Books of Lipids
• Books of Lipoproteins
• Books of Lipoproteins, HDL
• Books of Lipoproteins, LDL
• Books of Lipoproteins, VLDL
• Books of Metabolism
• Books of Obesity, Abdominal
• Books of PPAR delta
• Books of Thiazoles
• Books of Triglycerides